Marine Lipid Composition Omega-3 Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current marine lipid compositions, particularly those containing omega-3 fatty acids, face challenges in bioavailability and efficacy, especially in pathological conditions and pre-term infants, with absorption rates being lower compared to other fatty acids, and existing formulations may not efficiently reduce inflammation or improve the EPA/AA ratio in tissues.
Innovation Solution
A novel marine lipid composition comprising a specific ratio of omega-3 rich phospholipids and triglycerides, with a phospholipid structure containing DHA and EPA, is developed, which enhances the uptake and tissue incorporation of omega-3 fatty acids, improves the AA/EPA ratio, and reduces inflammatory biomarkers, formulated into food products, animal feed, and pharmaceutical compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If omega-3 fatty acids are administered as triglycerides or phospholipids, then anti-inflammatory properties are achieved, but bioavailability and tissue incorporation efficiency are limited
Solution Approach 1:
The patent combines omega-3 rich triglycerides and omega-3 rich phospholipids in a specific ratio (1:10 to 10:1) to create a composite lipid composition. This composite structure leverages the complementary properties of both triglycerides (high energy density, good palatability) and phospholipids (enhanced absorption, membrane integration) to achieve superior bioavailability and tissue incorporation compared to either component alone, while maintaining reliable anti-inflammatory efficacy
2Reliability
If marine lipid compositions are used in pathological conditions and pre-term infants, then anti-inflammatory effects are achieved, but absorption rates are lower compared to other fatty acids
Solution Approach 1:
The patent optimizes the ratio parameter of omega-3 rich triglycerides to omega-3 rich phospholipids (1:10 to 10:1) to enhance absorption kinetics. The phospholipid component facilitates micelle formation and intestinal uptake, particularly benefiting pre-term infants and pathological conditions where absorption capacity is compromised, thereby improving productivity (absorption rate) while maintaining the reliable anti-inflammatory effect
3Quantity of substance
If existing marine lipid formulations are used, then omega-3 supplementation is provided, but the EPA/AA ratio in tissues is not efficiently improved
Solution Approach 1:
The composite lipid composition combines triglycerides and phospholipids in optimized ratios, where the phospholipid fraction (containing phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, and phosphatidylinositol) facilitates efficient cellular uptake and membrane incorporation of EPA. This composite structure achieves precise modification of the EPA/AA ratio in tissue phospholipids, overcoming the limitation of existing formulations that fail to efficiently alter tissue fatty acid composition
Data Source
AI summary
Novel marine lipid compositions comprising triglycerides and omega-3 rich phospholipids are described. The compositions are characterized by providing highly bioavailable omega-3, increased tissue incorporation of omega-3 and reduced concentration of pro-inflammatory cytokines.